MediWound (MDWD) Competitors

$14.23 -0.04 (-0.28%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$14.22 -0.02 (-0.11%)

As of 07/24/2026 07:34 PM Eastern

MDWD vs. DSGN, DRUG, ZVRA, MNPR, and AURA

Should you buy MediWound stock or one of its competitors? MarketBeat compares MediWound with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MediWound include Design Therapeutics (DSGN), Bright Minds Biosciences (DRUG), Zevra Therapeutics (ZVRA), Monopar Therapeutics (MNPR), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry.

How does MediWound compare to Design Therapeutics?

MediWound (NASDAQ:MDWD) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

MediWound currently has a consensus price target of $34.00, indicating a potential upside of 138.93%. Design Therapeutics has a consensus price target of $16.50, indicating a potential upside of 40.07%. Given MediWound's higher probable upside, research analysts clearly believe MediWound is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Design Therapeutics had 1 more articles in the media than MediWound. MarketBeat recorded 2 mentions for Design Therapeutics and 1 mentions for MediWound. MediWound's average media sentiment score of 1.87 beat Design Therapeutics' score of 0.97 indicating that MediWound is being referred to more favorably in the media.

Company	Overall Sentiment
MediWound	Very Positive
Design Therapeutics	Positive

MediWound has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.78	-$23.88M	-$2.26	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Design Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Design Therapeutics' return on equity of -33.07% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Design Therapeutics	N/A	-33.07%	-31.29%

MediWound has a beta of 0.14, indicating that its stock price is 86% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

46.8% of MediWound shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 9.2% of MediWound shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Design Therapeutics beats MediWound on 11 of the 16 factors compared between the two stocks.

How does MediWound compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bright Minds Biosciences has higher earnings, but lower revenue than MediWound. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
MediWound	$16.96M	10.78	-$23.88M	-$2.26	N/A

Bright Minds Biosciences presently has a consensus target price of $143.83, suggesting a potential upside of 101.64%. MediWound has a consensus target price of $34.00, suggesting a potential upside of 138.93%. Given MediWound's higher probable upside, analysts clearly believe MediWound is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Bright Minds Biosciences has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Bright Minds Biosciences' return on equity of -20.58% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
MediWound	-180.30%	-67.22%	-31.87%

Bright Minds Biosciences has a beta of -5.34, meaning that its stock price is 634% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, meaning that its stock price is 86% less volatile than the broader market.

In the previous week, Bright Minds Biosciences had 4 more articles in the media than MediWound. MarketBeat recorded 5 mentions for Bright Minds Biosciences and 1 mentions for MediWound. MediWound's average media sentiment score of 1.87 beat Bright Minds Biosciences' score of 1.31 indicating that MediWound is being referred to more favorably in the news media.

Company	Overall Sentiment
Bright Minds Biosciences	Positive
MediWound	Very Positive

Summary

Bright Minds Biosciences beats MediWound on 9 of the 16 factors compared between the two stocks.

How does MediWound compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Zevra Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, meaning that its stock price is 86% less volatile than the broader market.

In the previous week, Zevra Therapeutics had 11 more articles in the media than MediWound. MarketBeat recorded 12 mentions for Zevra Therapeutics and 1 mentions for MediWound. MediWound's average media sentiment score of 1.87 beat Zevra Therapeutics' score of 0.45 indicating that MediWound is being referred to more favorably in the news media.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
MediWound	Very Positive

Zevra Therapeutics presently has a consensus price target of $29.29, indicating a potential upside of 207.62%. MediWound has a consensus price target of $34.00, indicating a potential upside of 138.93%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zevra Therapeutics has a net margin of 101.58% compared to MediWound's net margin of -180.30%. Zevra Therapeutics' return on equity of 51.49% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
MediWound	-180.30%	-67.22%	-31.87%

Zevra Therapeutics has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$122.29M	4.60	$83.23M	$1.99	4.78
MediWound	$16.96M	10.78	-$23.88M	-$2.26	N/A

Summary

Zevra Therapeutics beats MediWound on 12 of the 16 factors compared between the two stocks.

How does MediWound compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Monopar Therapeutics presently has a consensus target price of $112.08, indicating a potential upside of 2.01%. MediWound has a consensus target price of $34.00, indicating a potential upside of 138.93%. Given MediWound's higher probable upside, analysts clearly believe MediWound is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Monopar Therapeutics had 14 more articles in the media than MediWound. MarketBeat recorded 15 mentions for Monopar Therapeutics and 1 mentions for MediWound. MediWound's average media sentiment score of 1.87 beat Monopar Therapeutics' score of 0.92 indicating that MediWound is being referred to more favorably in the news media.

Company	Overall Sentiment
Monopar Therapeutics	Positive
MediWound	Very Positive

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Monopar Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, MediWound has a beta of 0.14, indicating that its stock price is 86% less volatile than the broader market.

Monopar Therapeutics has higher earnings, but lower revenue than MediWound. Monopar Therapeutics is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
MediWound	$16.96M	10.78	-$23.88M	-$2.26	N/A

Monopar Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Monopar Therapeutics' return on equity of -12.84% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
MediWound	-180.30%	-67.22%	-31.87%

Summary

Monopar Therapeutics beats MediWound on 11 of the 16 factors compared between the two stocks.

How does MediWound compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

MediWound has higher revenue and earnings than Aura Biosciences. MediWound is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
MediWound	$16.96M	10.78	-$23.88M	-$2.26	N/A

Aura Biosciences has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
MediWound	-180.30%	-67.22%	-31.87%

Aura Biosciences has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, meaning that its share price is 86% less volatile than the broader market.

Aura Biosciences presently has a consensus price target of $20.50, suggesting a potential upside of 190.78%. MediWound has a consensus price target of $34.00, suggesting a potential upside of 138.93%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Aura Biosciences and Aura Biosciences both had 1 articles in the media. Aura Biosciences' average media sentiment score of 1.89 beat MediWound's score of 1.87 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Aura Biosciences	Very Positive
MediWound	Very Positive

Summary

Aura Biosciences beats MediWound on 7 of the 12 factors compared between the two stocks.

Get MediWound News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDWD vs. The Competition

Export

Metric	MediWound	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$183.40M	$3.08B	$6.87B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-6.30	20.29	27.11	23.64
Price / Sales	10.78	485.19	517.09	89.57
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	4.19	4.13	10.28	6.07
Net Income	-$23.88M	$65.94M	$3.60B	$331.99M
7 Day Performance	-2.60%	-4.16%	-1.27%	-0.63%
1 Month Performance	-2.47%	-3.76%	-0.37%	-2.00%
1 Year Performance	-30.00%	9.94%	18.30%	13.62%

MediWound Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDWD MediWound	3.4913 of 5 stars	$14.23 -0.3%	$34.00 +138.9%	-31.8%	$183.40M	$16.96M	N/A	80
DSGN Design Therapeutics	2.4902 of 5 stars	$12.06 +1.6%	$16.50 +36.8%	+191.6%	$741.36M	N/A	N/A	40
DRUG Bright Minds Biosciences	3.1229 of 5 stars	$77.29 +3.6%	$143.83 +86.1%	+123.0%	$726.12M	N/A	N/A	N/A	News Coverage Positive News Analyst Upgrade
ZVRA Zevra Therapeutics	4.2172 of 5 stars	$12.45 +3.5%	$29.29 +135.2%	-18.4%	$711.15M	$106.47M	6.26	20	News Coverage Gap Down
MNPR Monopar Therapeutics	1.6419 of 5 stars	$113.57 +7.2%	$108.75 -4.2%	+134.7%	$709.43M	N/A	N/A	10	News Coverage Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDWD) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediWound (MDWD) Competitors

MDWD vs. DSGN, DRUG, ZVRA, MNPR, and AURA

How does MediWound compare to Design Therapeutics?

Summary

How does MediWound compare to Bright Minds Biosciences?

Summary

How does MediWound compare to Zevra Therapeutics?

Summary

How does MediWound compare to Monopar Therapeutics?

Summary

How does MediWound compare to Aura Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediWound (MDWD) Competitors

MDWD vs. DSGN, DRUG, ZVRA, MNPR, and AURA

How does MediWound compare to Design Therapeutics?

Do analysts rate MDWD or DSGN?

Does the media refer more to MDWD or DSGN?

Which has better valuation and earnings, MDWD or DSGN?

Is MDWD or DSGN more profitable?

Which has more risk & volatility, MDWD or DSGN?

Do institutionals and insiders have more ownership in MDWD or DSGN?

Summary

How does MediWound compare to Bright Minds Biosciences?

Do institutionals and insiders hold more shares of DRUG or MDWD?

Which has higher valuation and earnings, DRUG or MDWD?

Do analysts recommend DRUG or MDWD?

Is DRUG or MDWD more profitable?

Which has more risk & volatility, DRUG or MDWD?

Does the media favor DRUG or MDWD?

Summary

How does MediWound compare to Zevra Therapeutics?

Which has more risk & volatility, ZVRA or MDWD?

Does the media prefer ZVRA or MDWD?

Do analysts rate ZVRA or MDWD?

Do institutionals and insiders believe in ZVRA or MDWD?

Is ZVRA or MDWD more profitable?

Which has better valuation and earnings, ZVRA or MDWD?

Summary

How does MediWound compare to Monopar Therapeutics?

Do analysts prefer MNPR or MDWD?

Does the media favor MNPR or MDWD?

Do insiders and institutionals believe in MNPR or MDWD?

Which has more volatility and risk, MNPR or MDWD?

Which has preferable earnings & valuation, MNPR or MDWD?

Is MNPR or MDWD more profitable?

Summary

How does MediWound compare to Aura Biosciences?

Which has stronger earnings and valuation, AURA or MDWD?

Is AURA or MDWD more profitable?

Which has more volatility and risk, AURA or MDWD?

Do analysts rate AURA or MDWD?

Do institutionals & insiders hold more shares of AURA or MDWD?

Does the media prefer AURA or MDWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDWD vs. The Competition

MediWound Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools